Literature DB >> 11448927

Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF).

B I Lord1, L B Woolford, G Molineux.   

Abstract

Filgrastim G-CSF has a short, biologically active half-life, and its effective use depends on repeated inoculations. A major aim, therefore, has been to develop a once-per-chemotherapy cycle formulation. To this end, a polyethylene glycolylated form of Filgrastim, known as SD/01, has been developed. In this study, we compared the cellular kinetics of granulocyte production in mice stimulated with SD/01 and granulocyte colony-stimulating factor (G-CSF). Mice were injected with a single dose of SD/01 (1 mg/kg) or G-CSF (125 microg/kg) twice per day for 4 days. Mice rendered leukopenic with a single injection of cyclophosphamide (200 mg/kg) and temozolomide (90 mg/kg) were similarly treated at their 3-day neutrophil nadir. Tritiated thymidine was injected for autoradiographic labeling studies. Bone marrow labeling indices and the release of labeled neutrophils and monocytes into the peripheral blood were assessed. Granulocytopoiesis was stimulated similarly by both SD/01 and G-CSF in both normal and neutropenic animals, with counts rising to >20 x 10(9) polymorphonuclear neutrophils/l in both cases. Bone marrow thymidine labeling indices were increased, indicating a greater proportion of cells in DNA synthesis and an elevated proliferative activity. Compared with the normally slow release of neutrophils into the peripheral blood, labeled neutrophils (and monocytes) were rapidly released, increasing to peak levels at approximately 24 h. The peripheral half-life of neutrophils was not significantly different from normal, and the mitotic amplification factors for increase in granulocytopoiesis, accounted for by 3-3.9 extra cell divisions, were comparable for both factors. We conclude that neutrophil kinetics are stimulated in the same way and to the same extent by both SD/01 and G-CSF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448927

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  27 in total

1.  Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function.

Authors:  Desiree A Steimer; Kelli Boyd; Osamu Takeuchi; Jill K Fisher; Gerard P Zambetti; Joseph T Opferman
Journal:  Blood       Date:  2008-12-08       Impact factor: 22.113

2.  A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor.

Authors:  Wenbo Chen; Britton Boras; Tae Sung; Yanke Yu; Jenny Zheng; Diane Wang; Wenyue Hu; Mary E Spilker; David Z D'Argenio
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-03-11       Impact factor: 2.745

Review 3.  Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.

Authors:  Jeffrey Crawford
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  P-selectin glycoprotein ligand-1 deficiency augments G-CSF induced myeloid cell mobilization.

Authors:  Kornél Miszti-Blasius; Szabolcs Felszeghy; Csongor Kiss; Ilona Benkő; Krisztina Géresi; Attila Megyeri; Zsuzsanna Hevessy; János Kappelmayer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-10-05       Impact factor: 3.000

5.  The effect of recombinant granulocyte colony-stimulating factor on oral and periodontal manifestations in a patient with cyclic neutropenia: a case report.

Authors:  Sergio Matarasso; Vincenzo Daniele; Vincenzo Iorio Siciliano; Michele D Mignogna; Gianmaria Andreuccetti; Carlo Cafiero
Journal:  Int J Dent       Date:  2010-02-18

6.  Combined Therapy of Pegylated G-CSF and Alxn4100TPO Improves Survival and Mitigates Acute Radiation Syndrome after Whole-Body Ionizing Irradiation Alone and Followed by Wound Trauma.

Authors:  Juliann G Kiang; Min Zhai; David L Bolduc; Joan T Smith; Marsha N Anderson; Connie Ho; Bin Lin; Suping Jiang
Journal:  Radiat Res       Date:  2017-08-29       Impact factor: 2.841

7.  Rapid deletional peripheral CD8 T cell tolerance induced by allogeneic bone marrow: role of donor class II MHC and B cells.

Authors:  Thomas Fehr; Sophia Wang; Fabienne Haspot; Josef Kurtz; Peter Blaha; Timothy Hogan; Meredith Chittenden; Thomas Wekerle; Megan Sykes
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

8.  Filgrastim improves survival in lethally irradiated nonhuman primates.

Authors:  Ann M Farese; Melanie V Cohen; Barry P Katz; Cassandra P Smith; Allison Gibbs; Daniel M Cohen; Thomas J MacVittie
Journal:  Radiat Res       Date:  2012-12-04       Impact factor: 2.841

9.  Halichondrin B amide acts as tubulin binding agent to exhibit anti-tumor efficacy in hematologic cancers.

Authors:  Ying-Chun Li; Rong Zhang; Ying Yang; Jia Li; Ke Zhu; Kun Yao; Zhuo-Gang Liu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

10.  Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model.

Authors:  Markus Scholz; Manuela Ackermann; Frank Emmrich; Markus Loeffler; Manja Kamprad
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.